The p38 pathway is activated in Pick disease and progressive supranuclear palsy: A mechanistic link between mitogenic pathways, oxidative stress, and tau

Neurobiology of Aging

Volumn 23, Issue 5, 2002, Pages 855-859

  Hartzler, Anthony W ^a   Zhu, Xiongwei ^a   Siedlak, Sandra L ^a   Castellani, Rudolph J ^a   Avilá, Jesus ^b   Perry, George ^a   Smith, Mark A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Cytoskeleton; Immunocytochemistry; MAP kinase; MKK6; Neurodegeneration; Neurofibrillary tangles; Oxidative stress; p38; Phosphorylated tau; Pick disease; Progressive supranuclear palsy; Signal transduction

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TAU PROTEIN;

ARTICLE; CELL INCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MITOGENESIS; NIEMANN PICK DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CYTOSKELETON; HUMANS; MAP KINASE KINASE 6; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROFIBRILLARY TANGLES; OXIDATIVE STRESS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PICK DISEASE OF THE BRAIN; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 0036752026     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(02)00029-5     Document Type: Article

References (32)

1. Albers D.S., Augood S.J., Martin D.M., Standaert D.G., Vonsattel J.P., Beal M.F. Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy. J. Neurochem. 73:1999;881-884.
2. Albers D.S., Augood S.J., Park L.C., Browne S.E., Martin D.M., Adamson J.et al. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J. Neurochem. 74:2000;878-881.
3. Albers D.S., Augood S.J. New insights into progressive supranuclear palsy. Trends Neurosci. 24:2001;347-352.
4. Castellani R., Smith M.A., Richey P.L., Kalaria R., Gambetti P., Perry G. Evidence for oxidative stress in Pick disease and corticobasal degeneration. Brain Res. 696:1995;268-271.
5. Dickson D.W. Neuropathology of Pick's disease. Neurology. 56(Suppl 4):2001;S16-20.
6. Ghatak N.R., Nochlin D., Hadfield M.G. Neurofibrillary pathology in progressive supranuclear palsy. Acta Neuropathol. (Berl.). 52:1980;73-76.
7. Girolami UD, Anthony Douglas C, Frosch MP. The central nervous system. In: Cotran RS, Kumar V, Collins T, editors. Robbins pathologic basis of disease. 6th ed. Philadelphia: Saunders, 1999. p. 1293-357.
8. Hensley K., Floyd R.A., Zheng N.Y., Nael R., Robinson K.A., Nguyen X.et al. p38 kinase is activated in the Alzheimer's disease brain. J. Neurochem. 72:1999;2053-2058.
9. Husseman J.W., Nochlin D., Vincent I. Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases. Neurobiol. Aging. 21:2000;815-828.
10. Kimura T., Ikeda K., Takamatsu J., Miyata T., Sobue G., Miyakawa T.et al. Identification of advanced glycation end products of the Maillard reaction in Pick's disease. Neurosci. Lett. 219:1996;95-98.
11. Kyriakis J.M., Avruch J. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J. Biol. Chem. 271:1996;24313-24316.
12. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23:1997;134-147.
13. Montine K.S., Kim P.J., Olson S.J., Markesbery W.R., Montine T.J. 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J. Neuropathol. Exp. Neurol. 56:1997;866-871.
14. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K.et al. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60:2001;759-767.
15. Odetti P., Garibaldi S., Norese R., Angelini G., Marinelli L., Valentini S.et al. Lipoperoxidation is selectively involved in progressive supranuclear palsy. J. Neuropathol. Exp. Neurol. 59:2000;393-397.
16. Ono K., Han J. The p38 signal transduction pathway activation and function. Cell Signal. 12:2000;1-13.
17. Paul A., Wilson S., Belham C.M., Robinson C.J., Scott P.H., Gould G.W.et al. Stress-activated protein kinases: activation, regulation and function. Cell Signal. 9:1997;403-410.
18. Pérez M., Cuadros R., Smith M.A., Perry G., Avilá J. Phosphorylated but not native, tau protein assembles following reaction with the lipid peroxidation product 4-hydroxy-2-nonenal. FEBS Lett. 486:2000;270-274.
19. Perry G., Stewart D., Friedman R., Manetto V., Autilio-Gambetti L., Gambetti P. Filaments of Pick's bodies contain altered cytoskeletal elements. Am. J. Pathol. 127:1987;559-568.
20. Perry G., Castellani R.J., Hirai K., Smith M.A. Reactive oxygen species mediate cellular damage in Alzheimer disease? J. Alzheimer Dis. 1:1998;45-55.
21. Pollock N.J., Mirra S.S., Binder L.I., Hansen L.A., Wood J.G. Filamentous aggregates in Pick's disease, progressive supranuclear palsy, and Alzheimer's disease share antigenic determinants with microtubule-associated protein, tau. Lancet. 2:1986;1211.
22. Reynolds C.H., Nebreda A.R., Gibb G.M., Utton M.A., Anderton B.H. Reactivating kinase/p38 phosphorylates tau protein in vitro. J. Neurochem. 69:1997;191-198.
23. Reynolds C.H., Betts J.C., Blackstock W.P., Nebreda A.R., Anderton B.H. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2 c-Jun N-terminal kinase and p38 and glycogen synthase kinase-3beta. J. Neurochem. 74:2000;1587-1595.
24. Sasaki N., Fukatsu R., Tsuzuki K., Hayashi Y., Yoshida T., Fujii N.et al. Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases. Am. J. Pathol. 153:1998;1149-1155.
25. Smith M.A., Kutty R.K., Richey P.L., Yan S.-D., Stern D., Chader G.J.et al. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am. J. Pathol. 145:1994;42-47.
26. Sternberger LA. Immunocytochemistry. 3rd ed. New York: Wiley, 1986.
27. Tabaton M., Whitehouse P.J., Perry G., Davies P., Autilio-Gambetti L., Gambetti P. Alz 50 recognizes abnormal filaments in Alzheimer's disease and progressive supranuclear palsy. Ann. Neurol. 24:1988;407-413.
28. Takeda A., Smith M.A., Avilá J., Nunomura A., Siedlak S.L., Zhu X.et al. In Alzheimer's disease heme oxygenase is coincident with Alz50 an epitope of τ induced by 4-hydroxy-2-nonenal modification. J. Neurochem. 75:2000;1234-1241.
29. Zhu X., Rottkamp C.A., Boux H., Takeda A., Perry G., Smith M.A. Activation of p38 kinase links tau phosphorylation oxidative stress and cell cycle-related events in Alzheimer disease. J. Neuropathol. Exp. Neurol. 59:2000;880-888.
30. Zhu X., Raina A.K., Rottkamp C.A., Aliev G., Perry G., Boux H.et al. Activation and redistribution of c-Jun N-terminal kinase/stress-activated protein kinase in degenerating neurons in Alzheimer's disease. J. Neurochem. 76:2001;435-441.
31. Zhu X., Rottkamp C.A., Hartzler A., Sun Z., Takeda A., Boux H.et al. Activation of MKK6 an upstream activator of p38 in Alzheimer's disease. J. Neurochem. 79:2001;311-318.
32. Zhu X., Castellani R.J., Takeda A., Nunomura A., Atwood C.S., Perry G.et al. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the two hit hypothesis. Mech. Aging Dev. 123:2001;39-46.